Enfusion, Inc. (NYSE:ENFN) Receives $9.33 Average Target Price from Analysts

Shares of Enfusion, Inc. (NYSE:ENFN) have been given a consensus rating of “Reduce” by the six analysts that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $9.33.

A number of research analysts recently commented on ENFN shares. Bank of America increased their price target on Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a report on Wednesday, March 13th. Morgan Stanley assumed coverage on Enfusion in a research note on Friday, May 10th. They set an “overweight” rating and a $11.00 price objective on the stock.

Insider Activity at Enfusion

In related news, Director Deirdre Somers sold 4,629 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the completion of the transaction, the director now owns 43,312 shares in the company, valued at approximately $363,820.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Deirdre Somers sold 4,629 shares of Enfusion stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $8.40, for a total value of $38,883.60. Following the sale, the director now directly owns 43,312 shares in the company, valued at approximately $363,820.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Bronwen Bastone sold 18,241 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total transaction of $147,934.51. Following the completion of the transaction, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The disclosure for this sale can be found here. Insiders sold a total of 36,318 shares of company stock valued at $296,688 in the last quarter. Insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Several institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System grew its position in Enfusion by 11.0% in the first quarter. California State Teachers Retirement System now owns 36,002 shares of the company’s stock worth $333,000 after buying an additional 3,556 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Enfusion during the 1st quarter worth $102,000. Quadrature Capital Ltd acquired a new position in shares of Enfusion in the 1st quarter worth $109,000. Vanguard Group Inc. raised its holdings in Enfusion by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock worth $33,792,000 after buying an additional 51,670 shares during the period. Finally, Bleakley Financial Group LLC purchased a new position in Enfusion during the 1st quarter worth approximately $176,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Trading Down 0.8 %

Shares of NYSE ENFN opened at $8.52 on Wednesday. The stock has a fifty day moving average price of $9.07 and a 200 day moving average price of $9.05. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.56. The company has a market cap of $1.09 billion, a P/E ratio of 284.09, a P/E/G ratio of 1.98 and a beta of 0.96.

Enfusion (NYSE:ENFN) last announced its earnings results on Thursday, May 9th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). The company had revenue of $48.05 million for the quarter, compared to analysts’ expectations of $47.67 million. Enfusion had a net margin of 1.40% and a return on equity of 6.60%. During the same quarter in the previous year, the business posted $0.04 earnings per share. On average, sell-side analysts forecast that Enfusion will post 0.09 EPS for the current fiscal year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.